Grace Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GRCE research report →
Companywww.acastipharma.com
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage.
- CEO
- Prashant Kohli
- IPO
- 2012
- Employees
- 4
- HQ
- Princeton, NJ, US
Price Chart
Valuation
- Market Cap
- $33.73M
- P/E
- -5.40
- P/S
- 0.00
- P/B
- 0.57
- EV/EBITDA
- -1.94
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -10.61%
- ROIC
- -15.75%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-9,568,000 · 25.56%
- EPS
- $-0.79 · 54.34%
- Op Income
- $-16,679,000
- FCF YoY
- -20.63%
Performance & Tape
- 52W High
- $5.18
- 52W Low
- $1.79
- 50D MA
- $3.53
- 200D MA
- $3.39
- Beta
- 0.32
- Avg Volume
- 784.20K
Get TickerSpark's AI analysis on GRCE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 8, 26 | Kavuru Vimal | other | 10,000 |
| Jan 8, 26 | Kottayil George | other | 10,000 |
| Jan 8, 26 | NEUGEBOREN EDWARD | other | 10,000 |
| Jan 8, 26 | DAVIS A BRIAN | other | 10,000 |
| May 9, 25 | Kottayil George | other | 10,000 |
| May 9, 25 | NEUGEBOREN EDWARD | other | 10,000 |
| May 9, 25 | DAVIS A BRIAN | other | 10,000 |
| May 9, 25 | Kavuru Vimal | other | 10,000 |
| Apr 14, 25 | Kumar Amresh | other | 30,000 |
| Apr 14, 25 | Macdonald R. Loch | other | 40,000 |
Our GRCE Coverage
We haven't published any research on GRCE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GRCE Report →